Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1205 participants.

Also called NCT07223593

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,205 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07223593
  • EU CT 2025-523283-21-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Brazil, Canada, China, France, Greece, India, Israel, Japan, Netherlands, Poland, Puerto Rico, Slovakia, South Korea, Taiwan, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07223593. Randomized; double masking; primary purpose treatment. Start 2025-10-31 (actual); primary completion 2028-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Acronym
ATTAIN-PAD
Condition
Peripheral Arterial Disease
Intervention (Drug)
Orforglipron
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct07223593
Content hash
87cde6adb2337b49bc709f81ca8391f3f8b336fc1ab7ddac55ec3f4df4cacc28